Register of
Medicinal Products

Product class: Authorized package
Medicinal product class: For human use
Package code: 1069691
Name of medicinal product: VEPESID
Active substances:
Etoposide
Estonian, English, Latin
ATC code: L01CB01
Dosage form: capsule, soft
Route of administration: oral use
Strengh: 100mg
Amount in package: 60TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Recurrent or refractory testicular cancer is indicated in combination with other approved chemotherapeutic agents for the treatment of recurrent or refractory testicular cancer in adults. Small cell lung cancer is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults. Hodgkin’s lymphoma is indicated in combination with other approved chemotherapeutic agents for the second line treatment of Hodgkin’s lymphoma in adults. Non-Hodgkin’s lymphoma is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory non-Hodgkin’s lymphoma in adults. Acute myeloid leukaemia is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory acute myeloid leukaemia in adults. Ovarian cancer is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults. is indicated for the treatment of platinum-resistant/refractory epithelial ovarian cancer in adults.
Safety features: Yes
Summary of product characteristics (SPC):  (last updated April 12, 2024)
Package information leaflet (PIL): EST  (last updated April 12, 2024)
Labelling:  (last updated July 29, 2019)
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: Cheplapharm Arzneimittel GmbH 
Marketing authorization number: 319400 
Marketing authorization issued on: August 23, 2000 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Mutual recognition 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: April 12, 2024
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere